Evidence map›Paper›PMID 37260888›Full record

ArticleHeliyon2023

Clinical investigation of use of Episil® oral solution in oral mucositis during radiotherapy for head and neck cancer.

Kanade Ito, Shiori Tokura, Itsuki Takazawa, Naomi Yoshida, Tohko Nakanishi, Kikue Akiyama, Yuki Onuma, Toshiko Adachi, Hiroyuki Harada, Hitomi Nojima and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Barrier-forming lipid solution for severe oral mucositis: effect on oral intake interruption in head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kanade ItoDepartment of Oral Care for Systemic Health Support, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Shiori TokuraDepartment of Oral Care for Systemic Health Support, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Itsuki TakazawaDepartment of Oral Health Care Education, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Naomi YoshidaDepartment of Oral Health Care Education, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Tohko NakanishiDepartment of Dental Hygiene, Tokyo Medical and Dental University Hospital, Japan.
Kikue AkiyamaDepartment of Dental Hygiene, Tokyo Medical and Dental University Hospital, Japan.
Yuki OnumaDepartment of Dental Hygiene, Tokyo Medical and Dental University Hospital, Japan.
Toshiko AdachiDepartment of Dental Hygiene, Tokyo Medical and Dental University Hospital, Japan.
Hiroyuki HaradaDepartment of Oral and Maxillofacial Surgical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Hitomi NojimaDepartment of Dental Radiology and Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Masahiko MiuraDepartment of Dental Radiology and Radiation Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Ryoichi YoshimuraDepartment of Radiation Therapeutics and Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Yuji KabasawaDepartment of Oral Care for Systemic Health Support, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
Tokyo Medical and Dental University · JPTokyo Medical and Dental University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Episil® is a bio adhesive barrier-forming oral liquid gel that has been used in recent years to relieve pain of oral mucositis (OM) with radiotherapy (RT) or chemoradiotherapy (CRT) in head and neck cancer (HNC) patients. We conducted a retrospective analysis of the clinical effects of Episil® on OM in these patients. Study design: Between June 2018 and May 2020, 65 patients with HNC were treated with RT or CRT at our hospital. Results: The median total RT dose was 50 Gy (range, 30-70 Gy) and the completion rate was 63/65 (97%). The median time to OM resolution was 47 (6-90) days and was significantly longer (53 [27-90] days) when the total RT dose was ≥51 Gy ( Conclusion: Although Episil® has been shown to be effective in improving the pain of OM caused by RT for HNC patients, and medical professionals are required to give careful attention to each patient.

Indexed as

Episil®Head and neck cancerOral mucositisRadiotherapy

Identifiers

PMID37260888
PMCPMC10227342
OpenAlexW4378070053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.